Integra LifeSciences Holdings Corporation
IART
$15.10
-$0.02-0.13%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.24% | 1.53% | 4.99% | 3.53% | 6.19% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.24% | 1.53% | 4.99% | 3.53% | 6.19% |
| Cost of Revenue | 6.27% | 9.91% | 9.63% | 9.86% | 11.51% |
| Gross Profit | -2.29% | -4.15% | 1.80% | -0.70% | 2.75% |
| SG&A Expenses | -0.31% | -0.49% | 5.25% | 7.78% | 11.89% |
| Depreciation & Amortization | 0.94% | 5.12% | 10.02% | 14.94% | 20.92% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.75% | 3.38% | 6.84% | 8.77% | 11.82% |
| Operating Income | -3.04% | -12.97% | -8.49% | -28.40% | -25.40% |
| Income Before Tax | -1,145.00% | -2,990.05% | -4,474.80% | -2,165.68% | -193.45% |
| Income Tax Expenses | -184.50% | -316.43% | -829.04% | -1,809.25% | -341.75% |
| Earnings from Continuing Operations | -1,612.31% | -7,338.77% | -7,469.30% | -2,216.99% | -171.97% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1,612.31% | -7,338.77% | -7,469.30% | -2,216.99% | -171.97% |
| EBIT | -3.04% | -12.97% | -8.49% | -28.40% | -25.40% |
| EBITDA | 0.10% | -3.92% | 4.70% | -8.47% | -9.65% |
| EPS Basic | -1,616.49% | -7,553.52% | -7,247.67% | -2,300.24% | -174.05% |
| Normalized Basic EPS | -17.86% | -33.27% | -25.15% | -43.80% | -36.81% |
| EPS Diluted | -1,609.44% | -7,417.75% | -7,030.35% | -2,356.29% | -175.70% |
| Normalized Diluted EPS | -17.86% | -33.27% | -25.15% | -43.78% | -36.75% |
| Average Basic Shares Outstanding | 0.14% | -0.43% | -1.04% | -2.16% | -3.04% |
| Average Diluted Shares Outstanding | 0.14% | -0.43% | -1.04% | -2.20% | -3.13% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |